日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant

一名新确诊乳腺癌的患者被发现携带TP53嵌合型可能致病变异。

Mistry, Hetal D; Adams, MacKenzie R; Taneja, Charu; Massingham, Lauren J; Dibble, Elizabeth H; Leonard, Kara L; Hart, Jesse; Lagos, Galina G; Fenton, Mary Anne

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer

在激素受体阳性/HER2阴性转移性乳腺癌的治疗过程中,制定个性化治疗方案

Singareeka Raghavendra, Akshara; Damodaran, Senthil; Barcenas, Carlos H; Fuqua, Suzanne A; Layman, Rachel M; Tripathy, Debu

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention

通过补水预防尿路结石:一项依从性干预的随机临床试验

Desai, Alana C; Maalouf, Naim M; Harper, Jonathan D; Sivalingam, Sri; Lieske, John C; Lai, H Henry; Reese, Peter P; Wessells, Hunter; Yang, Hongqiu; Al-Khalidi, Hussein R; Kirkali, Ziya; Tasian, Gregory E; Scales, Charles D Jr

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer

阿特珠单抗联合FOLFOX方案治疗III期错配修复缺陷型结肠癌

Sinicrope, Frank A; Ou, Fang-Shu; Arnold, Dirk; Peters, Walter R; Behrens, Robert J; Lieu, Christopher H; Matin, Khalid; Cohen, Deirdre J; Potter, Samara L; Nixon, Andrew B; Kottschade, Lisa A; Kathol, Emily; Frankel, Wendy L; Shergill, Ardaman; Hsu, Dennis; Reinacher-Schick, Anke; Mehan, Paul; Gold, Philip J; Khalil, Maged F; Zemla, Tyler; Gatten, Clare; O'Reilly, Eileen M; Meyerhardt, Jeffrey A

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

非小细胞肺癌软脑膜转移的演变格局:一项国际性、当代、多中心队列研究

Zheng, M M; Xia, Y; Pan, K; Sun, F; Tan, A C; Dong, X R; Tu, H Y; Tang, L B; Li, Y S; Yin, K; Borgeaud, M; Singhal, S; Zhu, E; Zhang, J; Nilsson, M; Wu, J; Gibbons, D L; Wakelee, H; Neal, J W; Lee, J; Vaporciyan, A A; Ringsurongkawong, W; Tran, H T; Zhang, R Z; Zhang, T; Zhou, Q; Zhong, W Z; Li, W; Zhang, Y C; Riess, J W; Addeo, A; Heymach, J V; Myall, N; Tan, D; Wu, Y L; Le, X

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中,对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N

Dynamics of Solvating Water As a Probe of Polymers and Supramolecular Structures

溶剂化水的动力学作为聚合物和超分子结构的探针

Boeije, Willemijn H; Bakker, Huib J

P-096 A SUBMENTAL ECTOPIC THYROID GLAND: CASE REPORT OF STRANGE PRESENTATION

P-096 颏下异位甲状腺:一例罕见病例报告

Cappola, Anne R; Fried, Linda P; Arnold, Alice M; Danese, Mark D; Kuller, Lewis H; Burke, Gregory L; Tracy, Russell P; Ladenson, Paul W; Al-Waeli, Dheyaa Kadhim; Mohammed, Adel Gassab; Al Maged, Qeethar Khalid; Mosa, Hameed Naeem